Why Contract Research Organizations are Altering the Pharmaceutical...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Why Contract Research Organizations are Altering the Pharmaceutical Value Chain

Samuel Jackson, Quality Manager, Zoetis

Why Contract Research Organizations are Altering the Pharmaceutical Value ChainSamuel Jackson, Quality Manager, Zoetis

Contract Research and manufacturing over the last couple of decades altered the way how Pharma industries have been functioning.

The pharmaceutical industry has numerous unusual characteristics that make it very different from the way people think of it as an industry. It is, without question, among the riskiest businesses. From the genesis, Contract Research Organizations (CROs) have always faced two primary challenges like low-profit margin and limited market capitalization. At present, the CRO industry is witnessing a supply chain disruption, moving it to hunt the upstream element of the pharmaceutical value chain. Therefore, a 3P (past, present, prospect) decision-tree model is formulated, bringing out the future of the CRO industry. The outlook on the potential transformation of the CRO industry will help the real-world practice and innovation of this business model.

Being a subdivision of the pharmaceutical industry, the Contract Research Organization (CRO) has a background that dates back to the development of Huntingdon Life Sciences and Charles River Laboratories in the last 1940s. Since then, it has been facing two core challenges, low-profit margin, and limited market capitalization. In the industry’s early days, the development of CROs has slowly increased due to the rising profitability of upstream pharmaceutical companies. Moreover, pharma’s return of R&D investment has significantly decreased the cost pressure. As a result, CROs are inclined towards chasing the upstream part of the pharmaceutical value chain, paving a way to supply chain disruption.Top Contract Research Organization Companies

There are three different ways for CROs to chase the upstream value chain according to the real-world business practices.

1. CROs, while competing with pharmaceutical companies, can lose their cost advantage after entering the business change, unless it turns into a pharma enterprise itself.

2. A diverse way is by cooperating with pharmaceutical companies, and the CROs will shift from the fee-for-service agreements to a much broader risk-sharing and complementary collaboration.

3. The traditional path is to compromise with pharmaceutical companies, and CROs can derive profits if they provide R&D services that surpass the expectation.

See Also: Top Biotech Technology Solution Companies

Weekly Brief

Read Also

Late Pack Customization: the Way to Optimize Pharma Supply Chain

Late Pack Customization: the Way to Optimize Pharma Supply Chain

Tomasz Nawrocki, Pharmaceutical Supply Chain Service Department Director/ CEO Synoptis Industrial, Grupa NEUCA
What the New EMA Draft

What the New EMA Draft "Guideline on Computerized Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Parexel, Director, Technology Quality Assurance
How Contract Research Organisations Can Help the Pharma Companies

How Contract Research Organisations Can Help the Pharma Companies

Skye Fitzgerald, Data Analytics Manager, Jazz Pharmaceuticals
Why are Contract Research Organizations Significant in the Pharma Industry?

Why are Contract Research Organizations Significant in the Pharma Industry?

Willie Martin, Director, Discovery Process, Alkermes
How can Manufacturing Companies Keep Pace with the Shifting Trends of Oncology Drug Development

How can Manufacturing Companies Keep Pace with the Shifting Trends of Oncology Drug Development

Stewart Campbell, VP & General Manager at West Pharmaceutical & Li Chen, VP & General Manager at West Pharmaceutical
Optimizing Alkermes' R&D Model for Success

Optimizing Alkermes' R&D Model for Success

Craig Hopkinson, M.D., CMO and Executive Vice President, Research and Development, Alkermes